LLY - ELI LILLY & Co
Close
795.26
-119.260 -14.996%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:46 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$914.52
-119.26
-13.04%
Fundamental analysis
71%
Profitability
90%
Dept financing
25%
Liquidity
50%
Performance
70%
Performance
5 Days
3.64%
1 Month
5.39%
3 Months
-13.94%
6 Months
-12.04%
1 Year
39.50%
2 Year
116.27%
Key data
Stock price
$795.26
DAY RANGE
$794.43 - $914.52
52 WEEK RANGE
$586.17 - $972.53
52 WEEK CHANGE
$36.83
DIVIDEND
$1.30
EX-DIVIDEND DATE
08/15/2024
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news